Prospective Evaluation Plan for Randomised Trials of Prostate Cancer Screening
暂无分享,去创建一个
[1] J. Larson. The MOS 36-Item Short form Health Survey , 1997, Evaluation & the health professions.
[2] B. G. Blijenberg,et al. European randomized study of screening for prostate cancer—The Rotterdam pilot studies , 1996, International journal of cancer.
[3] C Parkes,et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer , 1995, BMJ.
[4] H. D. de Koning,et al. European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam Pilot studies , 1995, Cancer.
[5] J. Gohagan,et al. The prostate, lung, colorectal, and ovarian cancer screening trial of the national cancer institute , 1995 .
[6] G P Murphy,et al. Report of the consensus workshop on screening and global strategy for prostate cancer , 1995, Cancer.
[7] A S Whittemore,et al. Prostate-specific antigen as predictor of prostate cancer in black men and white men. , 1995, Journal of the National Cancer Institute.
[8] M. Stampfer,et al. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.
[9] I. Thompson,et al. Chemoprevention of prostate cancer. , 2003, Urology.
[10] P. Knekt,et al. Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.
[11] J. Richie,et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.
[12] R. Kane,et al. Relative sensitivity and specificity of serum prostate specific antigen (PSA) level compared with age‐referenced PSA, PSA density, and PSA change , 1994, Cancer.
[13] H. Adami,et al. Ethics of a prostate cancer screening trial , 1994, The Lancet.
[14] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[15] E. Greenberg,et al. Changes in prostate cancer incidence and treatment in USA , 1994, The Lancet.
[16] N. Wald,et al. Report of the European Society for Mastology Breast Cancer Screening Evaluation Committee (1993) , 1993 .
[17] R. Kane,et al. Characteristics of prostate cancers detected in a multimodality early detection program , 1993 .
[18] W. Catalona,et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.
[19] C G Chute,et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.
[20] W. Ellis,et al. The inability of prostate specific antigen index to enhance the predictive the value of prostate specific antigen in the diagnosis of prostatic carcinoma. , 1993, The Journal of urology.
[21] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[22] I. Thompson,et al. Disease-specific survival following routine prostate cancer screening by digital rectal examination. , 1993, JAMA.
[23] P. Boyle,et al. Screening for prostate cancer--necessity or nonsense? , 1993, European journal of cancer.
[24] Franciscus M. Bentvelsen,et al. Modalities available for screening for prostate cancer. , 1993, European journal of cancer.
[25] A. Engeland,et al. Prostate-specific antigen in serum from blood donors with subsequent prostate cancer diagnosis. , 1993, European journal of cancer.
[26] R. Kane,et al. The relationship of prostate‐specific antigen to digital rectal examination and transrectal ultrasonography: Findings of the American cancer society national prostate cancer detection project , 2010, Cancer.
[27] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[28] E. Metter,et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.
[29] J. Goméz,et al. Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.
[30] K. Helzlsouer,et al. Prostate-specific antigen levels and subsequent prostate cancer: potential for screening. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[31] R. Hiatt,et al. Case-control study of screening for prostatic cancer by digital rectal examinations , 1991, The Lancet.
[32] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[33] Norman E. Breslow,et al. Statistical Methods in Cancer Research, Vol. II: The Design and Analysis of Cohort Studies. , 1990 .
[34] S. Torp-Pedersen,et al. Prostate Cancer: Comparison of Transrectal US and Digital Rectal Examination for Screening , 1988, Radiology.
[35] The management of clinically localized prostate cancer. , 1987, National Institutes of Health consensus development conference consensus statement.
[36] M. Blute,et al. Long-term followup of young patients with stage A adenocarcinoma of the prostate. , 1986, The Journal of urology.
[37] H. Watanabe,et al. Comparison of digital examination and transrectal ultrasonography for the diagnosis of prostatic cancer. , 1986, The Journal of urology.